MTOR and neoplasm: Our findings reveal that patients in cluster 1, characterized by higher TMB, more active proliferative signaling (PI3K/AKT/mTOR), and elevated Ki-67 expression, exhibited more aggressive tumor features and relatively poorer clinical outcomes.